TITLE

Seizure Prophylaxis in Patients With Brain Tumors: A Meta-analysis

AUTHOR(S)
Sirven, Joseph I.; Wingerchuk, Dean M.; Drazkowski, Joseph F.; Lyons, Mark K.; Zimmerman, Richard S.
PUB. DATE
December 2004
SOURCE
Mayo Clinic Proceedings;Dec2004, Vol. 79 Issue 12, p1489
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To assess whether antiepileptic drugs (AEDs) should be prescribed to patients with brain tumors who have no history of seizures. METHODS: We performed a meta-analysis of randomized controlled trials (1966-2004) that evaluated the efficacy of AED prophylaxis vs no treatment or placebo to prevent seizures in patients with brain tumors who had no history of epilepsy. Summary odds ratios (ORs) were calculated using a random-effects model. Three subanalyses were performed to assess pooled ORs of seizures in patients with primary glial tumors, cerebral metastases, and meningiomas. RESULTS: Of 474 articles found in the initial search, 17 were identified as primary studies. Five trials met inclusion criteria: patients with a neoplasm (primary glial tumors, cerebral metastases, and meningiomas) but no history of epilepsy who were randomized to either an AED or placebo. The 3 AEDs studied were phenobarbital, phenytoin, and valproic acid. Of the 5 trials, 4 showed no statistical benefit of seizure prophylaxis with an AED. Meta-analysis confirmed the lack of AED benefit at 1 week (OR, 0.91; 95% confidence interval [Cl] 0.45-1.83) and at 6 months (OR, 1.01; 95% Cl, 0.51-1.98) of follow-up. The AEDs had no effect on seizure prevention for specific tumor pathology, including primary glial tumors (OR, 3.46; 95% Cl, 0.32-37.47), cerebral metastases (OR, 2.50; 95% Cl, 0.25-24.72), and meningiomas (OR, 0.62; 95% Cl, 0.10-3.85). CONCLUSIONS: No evidence supports AED prophylaxis with phenobarbital, phenytoin, or valproic acid in patients with brain tumors and no history of seizures, regardless of neoplastic type. Subspecialists who treat patients with brain tumors need more education on this issue. Future randomized controlled trials should address whether any of the newer AEDs are useful for seizure prophylaxis.
ACCESSION #
15323694

 

Related Articles

  • Seizure Prognosis in Brain Tumors: New Insights and Evidence-Based Management. VECHT, CHARLES J.; KERKHOF, MELISSA; DURAN-PENA, ALBERTO // Oncologist;Jul2014, Vol. 19 Issue 7, p751 

    Brain tumor-related epilepsy (BTE) is common in low- and high-grade gliomas. The risk of seizures varies between 60% and 100% among low-grade gliomas and between 40% and 60% in glioblastomas. The presence of seizures in patients with brain tumors implies favorable and unfavorable factors....

  • Anticonvulsant Prophylaxis for Patients with Brain Tumours: Insights from Clinical Trials. Mason, Warren P. // Canadian Journal of Neurological Sciences;May2003, Vol. 30 Issue 2, p89 

    Discusses the study 'Prophylactic anticonvulsants in patients with brain tumour,' by Peter A. Forsyth and colleagues, which appeared in the May 2003 issue of the 'Canadian Journal of Neurological Sciences.' Problems posed by the use of anticonvulsants in patients with brain tumors; Patient...

  • Prophylactic Anticonvulsants in Patient with Brain Tumour. Forsyth, Peter A.; Weaver, Susan; Fulton, Dorcas; Brasher, Penelope M.A.; Sutherland, Garnette; Stewart, Doug; Hagen, Neil A.; Barnes, Penny; Cairncross, J. Greg; DeAngelis, Lisa M. // Canadian Journal of Neurological Sciences;May2003, Vol. 30 Issue 2, p106 

    Determines whether prophylactic anticonvulsants in brain tumor patients without prior seizures reduced seizure frequency. Percentage of patients who experienced seizures; Seizure-free survival rate; Early termination of the study because seizure and survival rates were much lower than expected.

  • Fluorofelbamate Roecklein, Bryan A.; Sacks, Harry J.; Mortko, Henry; Stables, James // Neurotherapeutics;Jan2007, Vol. 4 Issue 1, p97 

    Summary: The incidence of refractory seizures has remained at 30–40%, even with the approval of nine new anticonvulsants over the past 12 years. In attempts to reduce seizure frequency and severity, physicians routinely resort to combining two or more anticonvulsants, ideally with...

  • Prophylactic antiepileptic drugs in brain tumors: What evidence is enough evidence? Rathore, Chaturbhuj; Radhakrishnan, Kurupath // Neurology India;Mar/Apr2013, Vol. 61 Issue 2, p105 

    The article presents results of the studies that investigate the use of antiepileptic drugs (AEDs) in preventing seizures of patients with brain tumors. Based on the results of meta-analyses and randomized controlled trials (RCT), AEDs is not effective in preventing and improving seizures. They...

  • The Future of Prehospital Treatment of Convulsive Status Epilepticus. Kandula, Padmaja // Neurology Alert;May2012, Vol. 30 Issue 9, p66 

    SINCE THE INITIAL 1998 LANDMARK VETERAN'S ADMINISTRATION (VA) study, intravenous benzodiazepines have been first-line treatment for status epilepticus (SE). However, the VA cooperative study, like many others to follow, only studies an intravenous route of administration of acute abortive...

  • Magnesium Sulfate and Other Anticonvulsants for Women with Preeclampsia. FOGLEMAN, COREY D. // American Family Physician;6/1/2011, Vol. 83 Issue 11, p1269 

    Background: Eclampsia, the occurrence of a seizure in association with preeclampsia, is rare but potentially life-threatening. Magnesium sulfate is the drug of choice for treating eclampsia. This review assesses its use for preventing eclampsia. Objectives: To assess the effects of magnesium...

  • Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study. Koekkoek, Johan A. F.; Kerkhof, Melissa; Dirven, Linda; Heimans, Jan J.; Postma, Tjeerd J.; Vos, Maaike J.; Bromberg, Jacoline E. C.; van den Bent, Martin J.; Reijneveld, Jaap C.; Taphoorn, Martin J. B. // BMC Neurology;2014, Vol. 14 Issue 1, p2 

    Background Epilepsy is common in patients with a glioma. Antiepileptic drugs (AEDs) are the mainstay of epilepsy treatment, but may cause side effects and may negatively impact neurocognitive functioning and quality of life. Besides antiepileptic drugs, anti-tumour treatment, which currently...

  • Perampanel: A new agent for adjunctive treatment of partial seizures. FAULKNER, MICHELE A. // American Journal of Health-System Pharmacy;2/1/2014, Vol. 71 Issue 3, p191 

    Purpose. The pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of perampanel are reviewed. Summary. Perampanel, a first-in-class antiepileptic agent, was recently approved for use as adjunctive therapy for the treatment of resistant partial seizures in patients 12 years of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics